Source-grounded facts extracted from BAXTER INTERNATIONAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BAXTER INTERNATIONAL INC: Amended and restated bylaws to set board size range of not less than seven nor more than twelve directors (effective 2026-05-05).
“the Board approved a corresponding amendment and restatement of the Company’s Amended and Restated Bylaws (the “Amended Bylaws”) reflecting that the number of directors on the Board shall not be less than seven nor more than twelve”
BAXTER INTERNATIONAL INC: Amended charter to reduce minimum number of directors to seven with no stated maximum limit (effective 2026-05-05).
“the stockholders of the Company approved an amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to reduce the required minimum number of directors to seven with no stated maximum limit.”
BAXTER INTERNATIONAL INC reported first quarter of 2026 results: revenue $2.7 billion, EPS ($0.03). Guidance reaffirmed.
“BAXTER REPORTS FIRST-QUARTER 2026 RESULTS • Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis 1,2 • U.S. GAAP 3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03); adjusted diluted EPS from continuing operations of $0.36 • Reiterates full-year 2026 financial outlook”
BAXTER INTERNATIONAL INC incurred senior notes of $1,000,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 5.650% maturing December 15, 2035.
“$1,000,000,000 aggregate principal amount of the Company’s 5.650% Senior Notes due 2035”
BAXTER INTERNATIONAL INC incurred senior notes of $700,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 4.900% maturing December 15, 2030.
“$700,000,000 aggregate principal amount of the Company’s 4.900% Senior Notes due 2030”
BAXTER INTERNATIONAL INC incurred senior notes of $300,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 4.450% maturing February 15, 2029.
“the issuance by the Company of $300,000,000 aggregate principal amount of the Company’s 4.450% Senior Notes due 2029”
Chris Toth departed as Executive Vice President and Group President, Kidney Care at BAXTER INTERNATIONAL INC.
“In accordance with the terms and conditions of the Purchase Agreement, effective as of the Closing Date, Chris Toth ceased serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company.”
Nancy Schlichting was appointed as Lead Independent Director at BAXTER INTERNATIONAL INC.
“Nancy Schlichting was appointed Lead Independent Director”
Brent Shafer was appointed as Interim Chief Executive Officer and Chair at BAXTER INTERNATIONAL INC.
“the Board appointed Brent Shafer as interim CEO of the Company and Chair of the Board”
Joel Grade changed role as interim Chief Accounting Officer and Principal Accounting Officer at BAXTER INTERNATIONAL INC.
“Mr. Joel Grade will cease serving as the Company’s interim Chief Accounting Officer and Principal Accounting Officer and will continue serving as the Company’s Executive Vice President and Chief Financial Officer.”
Anita Zielinski was elected as Senior Vice President, Chief Accounting Officer and Controller at BAXTER INTERNATIONAL INC.
“elected Ms. Anita Zielinski as its Senior Vice President, Chief Accounting Officer and Controller, effective as of February 21, 2025”
Peter M. Wilver resigned as Director at BAXTER INTERNATIONAL INC.
“On November 18, 2024, Mr. Peter M. Wilver notified Baxter International Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”) and the Audit Committee and Compensation and Human Capital Committee thereof, effective December 31, 2024.”
Jeffrey (Jay) A. Craig was appointed as Director at BAXTER INTERNATIONAL INC.
“On September 8, 2024, Baxter International Inc. (the “ Company ”) appointed Jeffrey (Jay) A. Craig to its Board of Directors”
Joel Grade was appointed as Executive Vice President, Chief Financial Officer and Interim Chief Accounting Officer at BAXTER INTERNATIONAL INC.
“On September 3, 2024, the Board of Directors of the Company approved the appointment of Mr. Joel Grade, the Company’s Executive Vice President and Chief Financial Officer, as the Company’s Chief Accounting Officer and PAO on an interim basis, effective September 3, 2024, while continuing to serve in his current position.”
Brian Stevens resigned as Senior Vice President, Chief Accounting Officer and Controller at BAXTER INTERNATIONAL INC.
“On September 3, 2024, Baxter International Inc. (the “ Company ”) and Mr. Brian Stevens mutually agreed that he will resign from his role as the Company’s Senior Vice President, Chief Accounting Officer and Controller and principal accounting officer (“ PAO ”) and will no longer be an employee of the Company as of the same date.”
Chris Toth departed as Executive Vice President and Group President, Kidney Care at BAXTER INTERNATIONAL INC.
“Chris Toth will cease serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company”
BAXTER INTERNATIONAL INC shareholders approved Approval of Baxter International Inc. Amended and Restated 2021 Incentive Plan at the 2024-05-07 meeting.
“on May 7, 2024, Baxter International Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “2024 Annual Meeting”), at which the Company’s stockholders approved the Baxter International Inc. Amended and Restated 2021 Incentive Plan (the “Amended Plan”).”
BAXTER INTERNATIONAL INC: Amended and restated Certificate of Incorporation to permit officer exculpation under Delaware law (effective 2024-05-07).
“Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year As described under Item 5.07 of this Current Report on Form 8-K, at the 2024 Annual Meeting, the stockholders of the Company approved an amendment and restatement of the Company’s Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”) to permit the exculpation of certain officers of the Company to the extent permitted under Delaware law. On May 7, 2024, the Company filed the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, with such Amended and Restated Certificate of Incorporation becoming effective immediately upon filing.”
BAXTER INTERNATIONAL INC updated its first quarter 2024 guidance (raised).
“On May 2, 2024, Baxter International Inc. (the Company) issued an earnings press release for the period ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.